Tebotelimab
- Generic Name
- Tebotelimab
- Drug Type
- Biotech
- CAS Number
- 2245725-04-4
- Unique Ingredient Identifier
- L62556GPXB
- Background
Tebotelimab is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)).
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
- Conditions
- Untreated Mucosal or Acral Lentiginous MelanomaUnresectable, Recurrent or Metastatic Melanoma
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT04653038
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- Conditions
- Gastric CancerGastroesophageal Junction CancerHER2-positive Gastric Cancer
- Interventions
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 82
- Registration Number
- NCT04082364
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, United States
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 30
- Registration Number
- NCT04072900
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
Anti-PD-1 +/- RT for MSI-H Solid Tumors
- Conditions
- Microsatellite Instability HighColorectal CancerMismatch Repair Deficiency
- Interventions
- Combination Product: RT and Anti-PD-1
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT04001101
- Locations
- 🇺🇸
University of Colorado Hospital, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.